Le Lézard
Classified in: Health, Science and technology
Subjects: PLW, MAT

MMJ International Holdings Files US Patent Prior To FDA Study For Cannabinoid Treatment Medicine



RESTON, Va., Jan. 3, 2018 /PRNewswire-PRWeb/ -- MMJ International Holdings, the premier medical cannabis research company that is advancing the science of medical marijuana through patient clinical research and the operation of medical cannabis healthcare businesses, today announced that it has filed another patent invention with the United States Patent and Trademark Office that relates to pharmaceutical compounds and methods for treating and/or preventing symptoms associated with cannabinoid responsive diseases and disorders, such as Multiple Sclerosis (MS), and Huntington's disease (HD).

MMJ BioScience's disclosed invention generally relates to pharmaceutical compounds and methods for treating and/or preventing diseases and disorders that often manifest in hyper and/or hypokinetic movements symptoms, as well as the method of administering therapeutically-effective amounts of a pharmaceutical compound containing cannabinoids to Multiple Sclerosis (MS) and Huntington's (HD) disease patients in need of treatment. The disclosed invention further relates to cannabinoid pharmaceutical compounds where said compound contains at least some non-cannabinoid components.The MMJ BioScience has filed these patents to protect the delivery of its MMJ BioScience® product formulation for its upcoming multiple sclerosis FDA study which is progressing through the Federal Drug Administrations (FDA) regulatory process.

Dr. Bianca Weinstock-Guttman, MMJ BioScience's principal investigator, is a Professor of Neurology at the State University of New York at Buffalo who serves as Executive Director of the New York State Multiple Sclerosis Consortium. Dr. Weinstock-Guttman will oversee the FDA approved study exploring the potential therapeutic applications of cannabinoids for progressive multiple sclerosis patients.

In late 2017 MMJ BioScience had submitted an application with the United States Food and Drug Administration (FDA) for approval of a new pharmaceutical drug. Unlike other cannabis-type medicines, MMJ BioScience's medicine is plant derived. When approval is received from the FDA the new medicine would be on sale across America as an approved drug.

MMJ BioScience's expected approval by the FDA for its new medicine would have a major impact on the state to state emerging cannabis industry which is not federally legal. Most recently the FDA had issued several cease and desist letters to firms that are marketing unapproved cannabinoid products. Whereas non-pharmaceutical companies cannot export their products across state lines, MMJ BioScience would be able to sell its medicine in pharmacies once prescribed by physicians.

MMJ BioScience's discovery of a novel cannabinoid pharmacology through our network of world leading scientists, our intellectual property portfolio, proprietary formulations, processing, and regulatory expertise uniquely position us to develop and manufacture plant-derived cannabinoid formulations at sufficient quality and uniformity according to the FDA regulatory requirements for pharmaceutical development.

 

SOURCE MMJ International Holdings


These press releases may also interest you

at 12:00
The "Information Security Services - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America,...

at 12:00
ANAHEIM, Calif., June 21, 2018 /PRNewswire-PRWeb/ -- Uplive USA will be sponsoring the most exclusive VidCon After-Party in Anaheim with some of the most popular YouTube creators and influencers on the night of VidCon opening day. The event will be...

at 12:00
LendUp, the fast-growing fintech firm for the emerging middle class, today announced Capital One co-founder Nigel Morris joined as board chair, and Frank Rotman, an early Capital One employee and its longtime chief credit officer, joined as board...

at 12:00
The AT&T* AUDIENCE Network series "Mr. Mercedes," produced by Sonar Entertainment, is returning to San Diego Comic-Con July 19-21 with the cast and creators of season 2 for the "Mr. Mercedes Immersive Experience" and show panel....

at 12:00
CHICAGO, June 21, 2018 /PRNewswire-PRWeb/ -- Strive Consulting CEO, Ron Rother, has been recognized as a Top CEO in 2018 by Glassdoor Employees' Choice Award. Rother ranked #5 on the Top CEO list for the U.S. Small & Medium companies category....

at 12:00
FREDERICK, Md., June 21, 2018 /PRNewswire-PRWeb/ -- From June 13th to 15th 2018, Frederick Innovation Technology Center, Inc (FITCI) incubator/accelerator client Mesa Science Associates presented at The National Institutes of Health CounterACT...




News published on 3 january 2018 at 13:00 and distributed by: